Rescriptor Related Published Studies
Well-designed clinical trials related to Rescriptor (Delavirdine)
Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. [2005]
Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. [2003.02]
Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. [2003.01]
A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients. [2001.03]
Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group. [2000.11]
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. [2000.11]
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. [2000.07.28]
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). [2000.03]
Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. [1999.08.01]
ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. [1999.06]
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial. [1999.01]
Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients. [1997.09]
Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. [1997.06]
Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. [1997.05]
Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. [1997.01]
Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. [1996.07]
Well-designed clinical trials possibly related to Rescriptor (Delavirdine)
Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. [2008.02]
US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference? [2007.08]
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. [2004.04.01]
Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine. [2002.12]
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. [2002.09.01]
Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy. [2001.11]
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884. [2000.11.10]
Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. [2000.04]
Issues in combination antiretroviral therapy: a review. [1994]
Other research related to Rescriptor (Delavirdine)
Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. [2006.12.15]
Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. [2006.01]
Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. [2004.11]
Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers. [2004.07]
Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. [2003.05]
Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. [2002.12]
Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy. [2002.09.06]
Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations. [2001.05]
Delavirdine: a review of its use in HIV infection. [2000.12]
Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine. [2000.07]
Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine. [2000.06]
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection. [1999.04.30]
In situ determination of delavirdine mesylate particle size in solid oral dosage forms. [1999.04]
Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. [1998.07.30]
Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. [1998.07.01]
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. [1997.05]
Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. [1997.03]
HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. [1997.02.01]
Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. [1996]
Other possibly related research studies
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results. [2004.04]
Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). [2004.11]
Clinical utility of current NNRTIs and perspectives of new agents in this class under development. [2004.05]
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. [2003.12.05]
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. [2003.05]
Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. [2002]
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. [2001]
Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. [2001.07.05]
Understanding the reverse transcriptase inhibitors in HIV. [1998.11]
[New combination medications] [1997.06]
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. [2001.06]
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. [2001.03.01]
Clinical uses of non-nucleoside reverse transcriptase inhibitors. [2000.07]
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. [2000.01.28]
Tablet dissolution affected by a moisture mediated solid-state interaction between drug and disintegrant. [1999.12]
Efavirenz: resistance and cross-resistance. [1999.06]
Antiretrovirals. [1999.12]
[The successes and problems in the treatment of HIV infection: a biochemist's view] [1999.01]
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. [1998.06]
Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. [1997.11]
Pharmacology of antiretroviral drugs. [1999]
Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil. [2004.12]
Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. [2004.12.15]
Pharmacokinetics of antiretrovirals in pregnant women. [2004]
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. [2004.10]
Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors. [2004]
Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. [2004]
Antiviral drugs in current clinical use. [2004.06]
Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. [2004.01.31]
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy. [2003.10]
Gateways to clinical trials. [2002.12]
Gateways to clinical trials. [2002.11]
Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. [2002]
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. [2002.10.18]
[Therapeutic aspects of HIV/AIDS infected patients and evaluation of therapeutic protocols] [2001.12]
Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. [2002.04.01]
HIV-protease inhibitors alter retinoic acid synthesis. [2001.10.19]
New developments in anti-HIV chemotherapy. [2001.11]
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. [2001.06.15]
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. [2001.04.15]
Nonnucleoside reverse transcriptase inhibitors. [1997.10]
New developments in anti-HIV chemotherapy. [2001.01]
Saquinavir soft gelatin capsule: a comparative safety review. [2001]
Use of HIV protease inhibitors as pharmacoenhancers. [2001.02]
The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. [2001]
Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. [2000.11]
Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. [2000.09]
Drug interactions with cisapride: clinical implications. [2000.07]
[Non-nucleoside reverse transcriptase inhibitors] [2000.06]
In vitro evaluation of the effect of temporary removal of HIV drug pressure. [2000.06]
Lactic acidosis associated with stavudine administration: a report of five cases. [2000.01]
Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. [1999.09]
Unusual distributions of body fat in AIDS patients: a review of adverse events reported to the Food and Drug Administration. [1999.05]
Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. [1999.01]
Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. [1999.04]
Efavirenz. [1998.12]
Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. [1998.12]
|
